Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diarrhea during use of sunitinib and sorafenib
NL-OMON35932Phase 4Recruiting
- Sponsor
- Netherlands Comprehensive Cancer Organisation
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sunitinib and sorafenib in renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST), hepatocellular carcinoma (HCC) and 1 more (2 cohorts), sponsored by Netherlands Comprehensive Cancer Organisation. Started Sep 2011; status: recruiting.
02
Drugs
sunitinibsorafenib
03
Conditions
renal cell carcinoma (RCC)gastrointestinal stromal tumor (GIST)hepatocellular carcinoma (HCC)Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NL-OMON35932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35932.